TY - JOUR
T1 - LG839
T2 - Anti-obesity effects and polymorphic gene correlates of reward deficiency syndrome
AU - Blum, Kenneth
AU - Chen, Amanda L.C.
AU - Chen, Thomas J.H.
AU - Rhoades, Patrick
AU - Prihoda, Thomas J.
AU - Downs, B. William
AU - Waite, Roger L.
AU - Williams, Lonna
AU - Braverman, Eric R.
AU - Braverman, Dasha
AU - Arcuri, Vanessa
AU - Kerner, Mallory
AU - Blum, Seth H.
AU - Palomo, Tomas
N1 - Funding Information:
The authors appreciate the funding support of the PATH Medical & Research Foundation and LifeGen®, Inc. They especially appreciate the donations of Don Reuben, Eduardo Cruz, Rein Norma, and Elizabeth Daiber. The authors would like to thank Brian Meshkin for his comments.
PY - 2008
Y1 - 2008
N2 - Introduction: This study systematically assessed the weight management effects of a novel experimental DNA-customized nutraceutical, LG839 (LifeGen® , Inc., La Jolla, CA, USA). Methods: A total of 1058 subjects who participated in the overall D.I.E.T. study were genotyped and administered an LG839 variant based on polymorphic outcomes. A subset of 27 self-identified obese subjects of Dutch descent, having the same DNA pattern of four out of the five candidate genes tested (chi-square analysis) as the entire data set, was subsequently evaluated. Simple t tests comparing a number of weight management parameters before and after 80 days of treatment with LG839 were performed. Results: Significant results were observed for weight loss, sugar craving reduction, appetite suppression, snack reduction, reduction of late night eating (all P<0.01), increased perception of overeating, enhanced quality of sleep, increased happiness (all P<0.05), and increased energy (P<0.001). Polymorphic correlates were obtained for a number of genes (LEP, PPAR-ã2, MTHFR, 5-HT2A, and DRD2 genes) with positive clinical parameters tested in this study. Of all the outcomes and gene polymorphisms, only the DRD2 gene polymorphism (A1 allele) had a significant Pearson correlation with days on treatment (r=0.42, P=0.045). Conclusion: If these results are confirmed in additional rigorous, controlled studies, we carefully suggest that DNA-directed targeting of certain regulator genes, along with customized nutraceutical intervention, provides a unique framework and strategic modality to combat obesity.
AB - Introduction: This study systematically assessed the weight management effects of a novel experimental DNA-customized nutraceutical, LG839 (LifeGen® , Inc., La Jolla, CA, USA). Methods: A total of 1058 subjects who participated in the overall D.I.E.T. study were genotyped and administered an LG839 variant based on polymorphic outcomes. A subset of 27 self-identified obese subjects of Dutch descent, having the same DNA pattern of four out of the five candidate genes tested (chi-square analysis) as the entire data set, was subsequently evaluated. Simple t tests comparing a number of weight management parameters before and after 80 days of treatment with LG839 were performed. Results: Significant results were observed for weight loss, sugar craving reduction, appetite suppression, snack reduction, reduction of late night eating (all P<0.01), increased perception of overeating, enhanced quality of sleep, increased happiness (all P<0.05), and increased energy (P<0.001). Polymorphic correlates were obtained for a number of genes (LEP, PPAR-ã2, MTHFR, 5-HT2A, and DRD2 genes) with positive clinical parameters tested in this study. Of all the outcomes and gene polymorphisms, only the DRD2 gene polymorphism (A1 allele) had a significant Pearson correlation with days on treatment (r=0.42, P=0.045). Conclusion: If these results are confirmed in additional rigorous, controlled studies, we carefully suggest that DNA-directed targeting of certain regulator genes, along with customized nutraceutical intervention, provides a unique framework and strategic modality to combat obesity.
KW - LG839
KW - Neurotransmitters
KW - Obesity
KW - Reward deficiency syndrome
KW - Sugar craving behavior
KW - Weight loss
UR - http://www.scopus.com/inward/record.url?scp=58149357384&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=58149357384&partnerID=8YFLogxK
U2 - 10.1007/s12325-008-0093-z
DO - 10.1007/s12325-008-0093-z
M3 - Article
C2 - 18781289
AN - SCOPUS:58149357384
VL - 25
SP - 894
EP - 913
JO - Advances in Therapy
JF - Advances in Therapy
SN - 0741-238X
IS - 9
ER -